Monteleone, a recognized Life Sciences executive, will focus on new growth initiatives for the supply chain organization.

Horsham, Pa. — October 27, 2022. Global Clinical Trial Ancillary Supply Chain (CTASC™) leader Ancillare, LP, the first and only Life Sciences company dedicated to Ancillary Supply Chain for Phase I-IV clinical research, has appointed Jason Monteleone, MBA as its new President.

Monteleone joins Ancillare with over 25 years of experience in the healthcare, medical device, and life sciences industries. He most recently served as Chief Business and Strategy Officer at dMed-Clinipace — a global mid-sized CRO — and Chief Executive Officer at Clinipace prior to its 2021 merger with dMed. He presently serves as a Board Observer for the Drug Information Association (DIA), a global organization dedicated to uniting life sciences professionals across more than 80 countries to share insights and drive actions in healthcare product and life cycle management.

In prior years, Jason founded Pivotal Financial Consulting, a consultancy where he advised investors and companies in the clinical research sector, focused on acquisitions, growth and innovation. Jason was also Chief Financial Officer and Executive Vice President for Theorem Clinical Research – a global mid-sized Contract Research Organization acquired by Chiltern International in 2015.

“In my position at Ancillare, I look forward to pursuing growth strategies that will take this innovative organization to the next level,” Monteleone said. “Ancillare has solved a major pain point in clinical trial operations. In a fast-growing Clinical Trial Equipment and Ancillary Solutions market, it is poised to become the leading mid-sized global ancillary clinical supplies and logistics partner.”

As President, Monteleone will identify opportunities and strategies for the organization’s growth, applying expertise in sales, talent acquisition and development, and market expansion.

“Jason’s extensive experience serving the clinical research industry will be instrumental to Ancillare as we enter a new stage of growth,” said Dr. Joanne Santomauro, Chief Executive Officer. “We are excited to welcome him to the team. His expertise will embrace and enhance our goals to expand our global footprint, add new services, strengthen our partnerships, and deliver excellence to all our Sponsors.”

About Ancillare, LP
Ancillare is the first and only Life Sciences company dedicated to Clinical Trial Ancillary Supply Chain (CTASC™) for Phase I-IV clinical research. Ancillare arms Sponsors of global clinical trials with customized, end-to-end supply plans, enabling developers of new therapies to optimize their supply chains using streamlined processes, extensive global buying power, a vast depot network, and proven teams of clinical, procurement, operations, logistics and regulatory experts. Ancillare’s industry-shaping model navigates the complexities of the Clinical Trial Ancillary Supply Chain to reduce both the overall cost and cycle time of clinical trials, and greatly improve operational efficiency across all levels of the value chain.

Ancillare has supported more than 8,000 clinical trials across 550,000 clinical sites in over 100 countries with corporate offices in the United States and the Netherlands, and distribution hubs in Argentina, Brazil, Canada, China, India, Israel, Japan, Korea, Philippines, Taiwan, Turkey, and United Kingdom. To learn more, visit Ancillare.com.

Leading life sciences supply chain organization announces new professional development resources for its staff.

Horsham, Pa. — May 31, 2022. Global Clinical Trial Ancillary Supply Chain (CTASC™) leader Ancillare, LP, the first and only Life Sciences company dedicated to Ancillary Supply Chain for Phase I-IV clinical research, is proud to announce the official launch of Ancillare University, a set of professional development courses for its staff.

Ancillare University includes a variety of resources for professionals at all levels, including Leadership and Executive courses, preparation for Project Management Certifications, Technology training, and more. The program became available to employees earlier this year and is fully accessible to its remote-first workforce.

In addition to the educational resources it offers internally, Ancillare also offers a tuition assistance program for employees advancing their careers through higher education.

“Ancillare University is designed to help our employees build more fulfilling, growth-oriented careers,” said Dr. Joanne Santomauro, Chief Executive Officer. “As an organization built on innovation, it is highly important that we continue to invest in our workforce.”

Ancillare is currently hiring for a variety of roles in Project Management, Clinical Operations, Procurement, Technology, and more. To learn more about open positions and available benefits, visit Ancillare.com/Careers.

About Ancillare, LP
Ancillare is the first and only Life Sciences company dedicated to Clinical Trial Ancillary Supply Chain (CTASC™) for Phase I-IV clinical research. Ancillare arms Sponsors of global clinical trials with customized, end-to-end supply plans, enabling developers of new therapies to optimize their supply chains using streamlined processes, extensive global buying power, a vast depot network, and proven teams of clinical, procurement, operations, logistics and regulatory experts. Ancillare’s industry-shaping model navigates the complexities of the Clinical Trial Ancillary Supply Chain to reduce both the overall cost and cycle time of clinical trials, and greatly improve operational efficiency across all levels of the value chain.

Ancillare has supported more than 8,000 clinical trials across 550,000 clinical sites in over 100 countries with corporate offices in the United States and the Netherlands, and distribution hubs in Argentina, Brazil, Canada, China, Israel, Japan, South Korea, Mexico, Philippines, Russia, Taiwan, and Ukraine. To learn more, visit Ancillare.com.

Leading life sciences supply chain organization promotes adoption of decentralized clinical trials alongside fellow industry leaders.

Horsham, Pa. — February 8, 2022. Global Clinical Trial Ancillary Supply Chain (CTASC™) leader Ancillare, LP, the first and only Life Sciences company dedicated to Ancillary Supply Chain for Phase I-IV clinical research, announced today it has joined the Decentralized Trials & Research Alliance (DTRA), an historic alliance of over one hundred life sciences and healthcare organizations that seeks to accelerate the broad adoption of patient-focused, decentralized clinical trials and research.

The “Decentralized Trials & Research Alliance (DTRA),” which launched December 2020, is uniting industry stakeholders, including healthcare companies, regulators, patient groups and research organizations with a singular mission to make clinical trial participation widely accessible by advancing policies, research practices and new technologies in decentralized clinical research.

“Decentralized trials are the future of clinical research, and a well-managed supply chain is foundational to their success,” said Dr. Joanne Santomauro, Chief Executive Officer, Ancillare. “As a member of the DTRA, Ancillare will help pave the way to broader adoption of decentralized trials through awareness and innovation of the global Clinical Trial Ancillary Supply Chain.”

“We are extremely gratified to welcome Ancillare to the ‘Decentralized Trials & Research Alliance,’” said Amir Kalali, MD, founder of several collaborative life science communities, and co-Chair of DTRA. “By advancing decentralized research we can make the clinical trial process more patient-focused, increase trial efficiency and encourage use of technologies. We are excited by Ancillare’s commitment to embracing decentralized trials and to changing the culture that has been the rate limiter to innovation.”

During the COVID-19 pandemic, Ancillare devoted greater focus to its Direct-to-Patient operation, which encompasses the assembly of ready-to-distribute single patient kits needed for decentralized research. The company is now expanding its facilities to accommodate enhanced kitting services for Sponsors conducting decentralized trials.

“Now is the time to share ideas and insights that will chart the future course of clinical trials, accelerating drug development and saving lives – and by taking part in the DTRA, Ancillare is demonstrating its leadership to drive change,” said Craig Lipset, DTRA co-Chair, clinical innovation advisor, and a pioneer in decentralized trials. “We have a responsibility to advance the health of people with unmet medical needs, and by convening stakeholders from pharma companies, regulators, technology leaders and patient communities, we can remove remaining barriers to adoption and impact patients today.”

To learn more about Ancillare’s work to advance clinical research through integrated supply chain strategies, visit Ancillare.com.

About Ancillare, LP
Ancillare is the first and only Life Sciences company dedicated to Clinical Trial Ancillary Supply Chain (CTASC™) for Phase I-IV clinical research. Ancillare arms Sponsors of global clinical trials with customized, end-to-end supply plans, enabling developers of new therapies to optimize their supply chains using streamlined processes, extensive global buying power, a vast depot network, and proven teams of clinical, procurement, operations, logistics and regulatory experts. Ancillare’s industry-shaping model navigates the complexities of the Clinical Trial Ancillary Supply Chain to reduce both the overall cost and cycle time of clinical trials, and greatly improve operational efficiency across all levels of the value chain.

Ancillare has supported more than 4,000 clinical trials across 200,000 clinical sites over 100 countries with corporate offices in the United States and the Netherlands, and distribution hubs in Argentina, Brazil, Canada, China, Israel, Japan, South Korea, Mexico, Netherlands, Philippines, Russia, Taiwan, and Ukraine. To learn more, visit Ancillare.com.

About DTRA
The Decentralized Trials & Research Alliance (DTRA) was convened to enable collaboration of stakeholders to accelerate the adoption of patient-focused, decentralized clinical trials and research within life sciences and healthcare through education and research. It works to make research participation accessible to everyone, enabled by the consistent, widespread adoption of appropriate decentralized research methods. Follow DTRA on Twitter and LinkedIn for more information.

Industry leader in Clinical Trial Ancillary Supply Chain announces plans to upgrade its headquarters in time for the new year

Horsham, Pa. — November 9, 2021. Global Clinical Trial Ancillary Supply Chain (CTASC™) leader Ancillare, LP, the first and only Life Sciences company dedicated to Ancillary Supply Chain for Phase I-IV clinical research, recently announced its purchase of office and warehouse space at 700 Enterprise Road in Horsham, Pennsylvania.

Strategically located in Greater Philadelphia, the new property is the second location owned by Ancillare within the pharma corridor of the northeastern United States. The company plans to renovate the space to accommodate expansion of its core capabilities, including kitting, labeling, and Direct-to-Patient operations. Initial upgrades to the office and warehouse facilities will be completed this year.

“As a partner to a number of the top global pharmaceutical companies, we are proud to continue building our physical infrastructure here in the Philadelphia area,” said Dr. Joanne Santomauro, Chief Executive Officer. “We are hard at work developing specialty services to address the unique challenges of the pandemic and its indelible impact on the global CTASC.”

In addition to its United States presence, the organization has a vast Global Distribution Network spanning North and South America, Europe, and Asia-Pacific, including a second headquarters in the Netherlands. For the most up-to-date information on Ancillare’s expansion efforts, visit Ancillare.com.

About Ancillare, LP

Ancillare is the first and only Life Sciences company dedicated to Clinical Trial Ancillary Supply Chain (CTASC™) for Phase I-IV clinical research. Ancillare arms Sponsors of global clinical trials with customized, end-to-end supply plans, enabling developers of new therapies to optimize their supply chains using streamlined processes, extensive global buying power, a vast depot network, and proven teams of clinical, procurement, operations, logistics and regulatory experts. Ancillare’s industry-shaping model navigates the complexities of the Clinical Trial Ancillary Supply Chain to reduce both the overall cost and cycle time of clinical trials, and greatly improve operational efficiency across all levels of the value chain.

Ancillare has supported more than 4,000 clinical trials across 200,000 clinical sites over 100 countries with corporate offices in the United States and the Netherlands, and distribution hubs in Argentina, Brazil, Canada, China, Israel, Japan, South Korea, Mexico, Netherlands, Philippines, Russia, Taiwan, and Ukraine. To learn more, visit Ancillare.com.

Christopher Calabretta, an accomplished procurement and operations executive, brings three decades of supply chain expertise to Ancillare’s leadership team.

Horsham, Pa. — September 29, 2021. Global Clinical Trial Ancillary Supply Chain (CTASC™) leader Ancillare, LP, the first and only Life Sciences company dedicated to Ancillary Supply Chain for Phase I-IV clinical research, today announced it has appointed Christopher Calabretta as Vice President of Supply Chain.

Calabretta brings three decades of experience in supply chain for global healthcare and consumer products companies, including Johnson & Johnson, McNeil Consumer Products, Campbell Soup Company, and FritoLay®. His career is marked by several successful enterprise-wide initiatives carried out on a global scale, driven by a passion for delivering value to patients and consumers worldwide.

In his new role, Calabretta will lead Ancillare’s Procurement, Logistics, and U.S. Distributions teams, and will help advance the organization’s strategic growth initiatives.

“We are proud to welcome Christopher to our organization,” said Dr. Joanne Santomauro, Chief Executive Officer. “His depth of expertise in global supply chains will be a tremendous asset in Ancillare’s mission to innovate the global CTASC.”

About Ancillare, LP
Ancillare is the first and only Life Sciences company dedicated to Clinical Trial Ancillary Supply Chain (CTASC TM) for Phase I-IV clinical research. Ancillare arms Sponsors of global clinical trials with customized, end-to-end supply plans, enabling developers of new therapies to optimize their supply chains using streamlined processes, extensive global buying power, a vast depot network, and proven teams of clinical, procurement, operations, logistics and regulatory experts. Ancillare’s industry-shaping model navigates the complexities of the Clinical Trial Ancillary Supply Chain to reduce both the overall cost and cycle time of clinical trials, and greatly improve operational efficiency across all levels of the value chain.

Ancillare has supported more than 4,000 clinical trials across 200,000 clinical sites over 100 countries with a corporate office in the United States, and distribution hubs in Argentina, Brazil, Canada, China, Israel, Japan, South Korea, Mexico, Netherlands, Philippines, Russia, Taiwan, and Ukraine. To learn more, visit Ancillare.com.

Leading life sciences supply chain organization acquires NG BV, a Netherlands-based company authorized to procure, supply, and export medicinal products.

Horsham, Pa. — September 23, 2021. Global Clinical Trial Ancillary Supply Chain (CTASC™) leader Ancillare, LP, the first and only Life Sciences company dedicated to Ancillary Supply Chain for Phase I-IV clinical research, today announced its acquisition of NG BV in the Netherlands.

As a company with a Wholesale Distribution Authorization (WDA), NG BV will market, procure, supply, and export medicinal products. The acquisition deepens Ancillare’s supply chain capabilities in the medicinal products space, allowing even greater control and supply chain transparency for Sponsors globally.

“The purchase of NG BV is a significant milestone for our organization,” said Dr. Joanne Santomauro, Chief Executive Officer. “The ability to manage medicinal products that facilitate clinical trials reinforces our position as a single-source partner for CTASC management and significantly supports the industry-unique Ancillare Turn-Key Operation (A-TKO™).”

Cathy Porretti, Chief Global Operation Officer, added: “We know many Sponsors value single vendor relationships to ensure smooth, timely trials. And through this acquisition and expansion, we are able to bring our proven methodology to another key part of the trial’s lifecycle.”

In the coming months, more expansion efforts will take place to strengthen Ancillare’s global supply chain infrastructure and service offering. For the most up-to-date information on Ancillare’s CTASC capabilities, visit Ancillare.com.

About Ancillare, LP
Ancillare is the first and only Life Sciences company dedicated to Clinical Trial Ancillary Supply Chain (CTASC™) for Phase I-IV clinical research. Ancillare arms Sponsors of global clinical trials with customized, end-to-end supply plans, enabling developers of new therapies to optimize their supply chains using streamlined processes, extensive global buying power, a vast depot network, and proven teams of clinical, procurement, operations, logistics and regulatory experts. Ancillare’s industry-shaping model navigates the complexities of the Clinical Trial Ancillary Supply Chain to reduce both the overall cost and cycle time of clinical trials, and greatly improve operational efficiency across all levels of the value chain.

Ancillare has supported more than 4,000 clinical trials across 200,000 clinical sites over 100 countries with a corporate office in the United States, and distribution hubs in Argentina, Brazil, Canada, China, Israel, Japan, South Korea, Mexico, Netherlands, Philippines, Russia, Taiwan, and Ukraine. To learn more, visit Ancillare.com.